비만 관련 암 역학 분석 및 예측(2026-2035년)

Obesity has emerged as one of the most significant modifiable risk factors for cancer worldwide. Excess body weight contributes to chronic inflammation, insulin resistance, hormonal imbalances, adipokine dysregulation, and metabolic disturbances that increase the risk of multiple malignancies. Epidemiological evidence has established strong associations between obesity and several cancer types, including breast cancer, colorectal cancer, endometrial cancer, liver cancer, pancreatic cancer, kidney cancer, and esophageal adenocarcinoma. Growing obesity rates across both developed and developing economies are increasing the global burden of obesity-associated cancers and creating a greater need for comprehensive epidemiological analysis.

Epidemiology analysis provides critical insights into disease prevalence, incidence, mortality patterns, risk factor distribution, patient demographics, obesity-attributable cancer burden, and long-term healthcare impacts. Pharmaceutical companies, healthcare organizations, public health agencies, research institutions, and policymakers increasingly rely on epidemiological data to support prevention strategies, resource allocation, therapeutic development, and healthcare planning. As obesity continues to expand as a global health challenge, epidemiological intelligence is becoming an essential component of oncology research and disease management.

Market Drivers

Rising Global Obesity Prevalence

One of the most important drivers of market growth is the continued increase in obesity rates worldwide. Urbanization, sedentary lifestyles, unhealthy dietary patterns, and reduced physical activity are contributing to rising obesity prevalence across all age groups.

As obesity rates increase, healthcare systems are witnessing a corresponding rise in obesity-associated cancer incidence. This trend is generating substantial demand for epidemiological monitoring and long-term disease burden assessment.

Increasing Incidence of Obesity-Associated Cancers

Research has demonstrated strong links between obesity and multiple cancer types. Obesity contributes to increased risks of postmenopausal breast cancer, colorectal cancer, endometrial cancer, pancreatic cancer, liver cancer, kidney cancer, and several other malignancies.

The growing incidence of these cancers is encouraging healthcare organizations and research institutions to invest in advanced epidemiological studies and surveillance programs.

Expansion of Cancer Surveillance Programs

Governments and healthcare organizations are increasingly investing in cancer registries, disease surveillance networks, population health databases, and public health monitoring initiatives.

These programs improve data collection, disease tracking, and risk assessment capabilities, enabling more accurate evaluation of obesity-related cancer trends and future disease burden.

Growing Focus on Preventive Healthcare

Healthcare systems are placing greater emphasis on prevention-oriented healthcare models. Understanding obesity-attributable cancer risk is critical for designing effective prevention programs, lifestyle interventions, screening strategies, and public health policies.

The increasing importance of preventive oncology is strengthening demand for epidemiological analysis and population-level cancer intelligence.

Market Restraints

Variability in Data Collection Standards

Differences in healthcare infrastructure, cancer registry quality, obesity measurement methods, and reporting systems can create inconsistencies in epidemiological datasets.

Variations in data quality and collection practices may limit comparability across regions and affect the accuracy of global disease burden estimates.

Underreporting in Emerging Markets

Many developing countries continue to face challenges related to cancer diagnosis, disease registration, obesity monitoring, and healthcare access.

Limited surveillance infrastructure can result in underreporting of both obesity prevalence and obesity-associated cancer incidence, creating gaps in epidemiological assessments.

Complex Multifactorial Disease Relationships

Cancer development is influenced by numerous factors including genetics, environmental exposures, lifestyle behaviors, age, and socioeconomic conditions.

The complex interaction between obesity and other cancer risk factors can make it difficult to isolate obesity-specific contributions to disease incidence and outcomes.

Technology and Segment Insights

The global obesity-linked cancer epidemiology analysis market can be segmented by cancer type, risk factor category, demographic group, data source, application, end user, and geography.

By cancer type, the market includes breast cancer, colorectal cancer, endometrial cancer, liver cancer, pancreatic cancer, kidney cancer, esophageal adenocarcinoma, gallbladder cancer, ovarian cancer, thyroid cancer, and other obesity-associated malignancies. Breast, colorectal, and endometrial cancers represent major segments due to their well-established association with obesity and significant disease burden.

By risk factor category, the market includes obesity, overweight status, metabolic syndrome, insulin resistance, physical inactivity, dietary factors, and associated comorbidities such as diabetes and non-alcoholic fatty liver disease. Obesity remains the primary segment due to its direct role in cancer development and progression.

By demographic group, the market includes pediatric, adult, and geriatric populations, as well as gender-specific analyses. Adult and elderly populations account for a significant share due to the higher prevalence of both obesity and cancer among these groups.

By data source, the market includes cancer registries, electronic health records, hospital databases, insurance claims databases, public health surveillance systems, academic studies, and national health surveys. Cancer registries and population-based databases serve as critical sources for epidemiological analysis and disease tracking.

By application, the market includes prevalence analysis, incidence forecasting, mortality assessment, healthcare planning, risk stratification, prevention strategy development, clinical research support, and policy formulation. Disease burden assessment and preventive healthcare planning represent major application areas due to increasing focus on population health management.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, public health agencies, government organizations, contract research organizations, and healthcare consulting firms. Public health agencies and research institutions represent significant end-user groups because of their role in cancer surveillance and prevention initiatives.

Technological advancements are significantly enhancing epidemiological capabilities through artificial intelligence, machine learning, predictive analytics, genomics, digital health platforms, real-world evidence databases, and advanced population health modeling systems. These technologies improve disease forecasting, patient stratification, risk assessment, and healthcare planning efficiency.

The integration of obesity metrics, genomic information, lifestyle data, and cancer outcomes is enabling more sophisticated epidemiological models that support precision prevention strategies and targeted public health interventions.

Geographically, North America dominates the market due to high obesity prevalence, extensive cancer surveillance infrastructure, advanced healthcare systems, and strong investment in public health research. Europe maintains a substantial market position supported by comprehensive healthcare databases and cancer registries. Asia-Pacific is expected to experience significant growth owing to increasing obesity rates, expanding healthcare infrastructure, rising cancer incidence, and growing investments in epidemiological research. Latin America and the Middle East & Africa are gradually strengthening disease surveillance systems and cancer registry programs.

Competitive and Strategic Outlook

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, academic institutions, public health agencies, contract research organizations, and specialized healthcare intelligence companies. Organizations are increasingly investing in advanced analytics platforms, real-world evidence systems, digital registries, and population health databases to improve epidemiological accuracy and forecasting capabilities.

Strategic collaborations between healthcare providers, academic institutions, government agencies, and research organizations are becoming increasingly common as stakeholders seek to improve data quality and expand understanding of obesity-associated cancer risks.

The growing emphasis on precision prevention, population health management, and evidence-based healthcare planning is expected to create new opportunities for organizations providing epidemiological intelligence and cancer burden analysis solutions. As healthcare systems increasingly prioritize prevention-focused oncology strategies, demand for obesity-linked cancer epidemiology data is expected to remain strong.

Conclusion

The global obesity-linked cancer epidemiology analysis market is poised for sustained growth through 2031, driven by rising obesity prevalence, increasing incidence of obesity-associated cancers, expanding cancer surveillance programs, and growing emphasis on preventive healthcare. Epidemiological intelligence is becoming increasingly important for understanding disease burden, identifying high-risk populations, supporting therapeutic development, and guiding public health policy. Although challenges related to data consistency, underreporting, and multifactorial disease interactions remain, ongoing advancements in analytics, digital health technologies, and population health research are expected to significantly strengthen the value and impact of obesity-linked cancer epidemiology analysis worldwide.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Overview of Obesity-Linked Cancer Epidemiology
• 1.2 Scope and Objectives of the Report
• 1.3 Key Epidemiological Insights
• 1.4 Disease Burden Overview
• 1.5 Diagnosed and Treated Population Trends
• 1.6 Key Risk Factor Assessment
• 1.7 Screening and Early Detection Trends
• 1.8 Treatment Access Overview
• 1.9 Future Epidemiology Outlook
• 1.10 Strategic Public Health Implications

2. Disease Overview & Epidemiology Analysis

• 2.1 Introduction to Obesity-Linked Cancers
  • 2.1.1 Definition and Clinical Background
  • 2.1.2 Mechanistic Link Between Obesity and Cancer
  • 2.1.3 Adiposity-Driven Hormonal and Metabolic Alterations
  • 2.1.4 Chronic Inflammation and Tumorigenesis
  • 2.1.5 Obesity, Insulin Resistance, and Cancer Progression
• 2.2 Classification of Obesity-Linked Cancers
  • 2.2.1 Breast Cancer
    • 2.2.1.1 Postmenopausal Breast Cancer
    • 2.2.1.2 Triple-Negative Breast Cancer
  • 2.2.2 Colorectal Cancer
  • 2.2.3 Endometrial Cancer
  • 2.2.4 Pancreatic Cancer
  • 2.2.5 Liver Cancer
  • 2.2.6 Esophageal Adenocarcinoma
  • 2.2.7 Kidney Cancer
  • 2.2.8 Ovarian Cancer
  • 2.2.9 Gastric Cardia Cancer
  • 2.2.10 Gallbladder Cancer
  • 2.2.11 Thyroid Cancer
  • 2.2.12 Multiple Myeloma
  • 2.2.13 Meningioma
• 2.3 Pathophysiology and Disease Mechanism
  • 2.3.1 Obesity-Induced Hormonal Dysregulation
  • 2.3.2 Hyperinsulinemia and IGF Signaling
  • 2.3.3 Adipokines and Cytokine Imbalance
  • 2.3.4 Oxidative Stress and DNA Damage
  • 2.3.5 Gut Microbiome Alterations and Cancer Risk
• 2.4 Epidemiology Overview
  • 2.4.1 Global Incidence Analysis
  • 2.4.2 Global Prevalence Analysis
  • 2.4.3 Mortality Analysis
  • 2.4.4 Survival Rate Assessment
  • 2.4.5 Obesity Prevalence vs Cancer Burden Correlation
  • 2.4.6 BMI-Based Risk Stratification
  • 2.4.7 Age-Wise Epidemiology
  • 2.4.8 Gender-Based Epidemiology
  • 2.4.9 Urban vs Rural Disease Burden
  • 2.4.10 Pediatric and Adolescent Obesity Trends
• 2.5 Epidemiology by Cancer Type
  • 2.5.1 Breast Cancer Epidemiology
  • 2.5.2 Colorectal Cancer Epidemiology
  • 2.5.3 Endometrial Cancer Epidemiology
  • 2.5.4 Liver Cancer Epidemiology
  • 2.5.5 Pancreatic Cancer Epidemiology
  • 2.5.6 Kidney Cancer Epidemiology
  • 2.5.7 Other Obesity-Associated Malignancies
• 2.6 Disease Burden and Healthcare Impact
  • 2.6.1 Hospitalization Trends
  • 2.6.2 Long-Term Care Burden
  • 2.6.3 Economic Burden Assessment
  • 2.6.4 Quality-of-Life Impact
  • 2.6.5 Productivity Loss Analysis

3. Disease Dynamics

• 3.1 Epidemiological Drivers
  • 3.1.1 Rising Global Obesity Rates
  • 3.1.2 Sedentary Lifestyle Trends
  • 3.1.3 Dietary Transition and Ultra-Processed Food Consumption
  • 3.1.4 Aging Population Dynamics
  • 3.1.5 Metabolic Syndrome Prevalence
• 3.2 Epidemiological Restraints
  • 3.2.1 Limited Early Cancer Detection
  • 3.2.2 Low Awareness in High-Risk Populations
  • 3.2.3 Screening Access Inequality
  • 3.2.4 Underdiagnosis in Developing Regions
• 3.3 Public Health Opportunities
  • 3.3.1 Expansion of Obesity Prevention Programs
  • 3.3.2 Population-Based Cancer Screening Initiatives
  • 3.3.3 Lifestyle Intervention Programs
  • 3.3.4 Precision Prevention Approaches
  • 3.3.5 AI-Driven Risk Prediction Models
• 3.4 Challenges in Disease Management
  • 3.4.1 Comorbidity Burden
  • 3.4.2 Treatment Complexity in Obese Patients
  • 3.4.3 Healthcare Infrastructure Limitations
  • 3.4.4 Long-Term Monitoring Challenges

4. Commercial & Treatment Access Landscape

• 4.1 Diagnosis and Screening Access
  • 4.1.1 Cancer Screening Uptake Trends
  • 4.1.2 Access to Diagnostic Imaging
  • 4.1.3 Molecular Diagnostic Adoption
  • 4.1.4 Population Risk Stratification Programs
• 4.2 Treatment Access Analysis
  • 4.2.1 Access to Surgical Oncology
  • 4.2.2 Access to Radiation Therapy
  • 4.2.3 Access to Targeted Therapy
  • 4.2.4 Access to Immunotherapy
  • 4.2.5 Healthcare Infrastructure Assessment
• 4.3 Reimbursement Landscape
  • 4.3.1 Public Reimbursement Frameworks
  • 4.3.2 Private Insurance Coverage
  • 4.3.3 Reimbursement Challenges for Oncology Care
  • 4.3.4 Coverage for Obesity Management Programs

5. Innovation & Clinical Development Landscape

• 5.1 Emerging Innovation Trends
  • 5.1.1 Precision Oncology Integration
  • 5.1.2 Metabolic Biomarker Development
  • 5.1.3 AI in Oncology Risk Assessment
  • 5.1.4 Liquid Biopsy Integration
  • 5.1.5 Obesity-Focused Preventive Oncology Programs
• 5.2 Pipeline Landscape by Development Stage
  • 5.2.1 Discovery Stage Research
  • 5.2.2 Preclinical Research Programs
  • 5.2.3 Phase I Clinical Trials
  • 5.2.4 Phase II Clinical Trials
  • 5.2.5 Phase III Clinical Trials
• 5.3 Pipeline Landscape by Mechanism of Action
  • 5.3.1 Immune Checkpoint Inhibitors
  • 5.3.2 Hormonal Therapies
  • 5.3.3 Targeted Therapies
  • 5.3.4 Metabolic Pathway Modulators
  • 5.3.5 Anti-Inflammatory Therapeutic Approaches
• 5.4 Clinical Trial Landscape
  • 5.4.1 Obesity-Associated Oncology Trials
  • 5.4.2 Combination Therapy Studies
  • 5.4.3 Biomarker-Driven Trials
  • 5.4.4 Lifestyle Intervention Studies

6. Treatment Landscape

• 6.1 Standard of Care Overview
  • 6.1.1 Surgery
  • 6.1.2 Radiation Therapy
  • 6.1.3 Chemotherapy
  • 6.1.4 Hormonal Therapy
  • 6.1.5 Immunotherapy
  • 6.1.6 Targeted Therapy
• 6.2 Approved Oncology Therapies Commonly Used in Obesity-Linked Cancers
  • 6.2.1 Pembrolizumab (Keytruda) - Merck & Co.
  • 6.2.2 Nivolumab (Opdivo) - Bristol Myers Squibb
  • 6.2.3 Trastuzumab (Herceptin) - Roche
  • 6.2.4 Bevacizumab (Avastin) - Roche
  • 6.2.5 Lenvatinib (Lenvima) - Eisai
  • 6.2.6 Palbociclib (Ibrance) - Pfizer
  • 6.2.7 Abemaciclib (Verzenio) - Eli Lilly and Company
  • 6.2.8 Pembrolizumab + Lenvatinib Combination Regimens
  • 6.2.9 Dostarlimab (Jemperli) - GSK plc
  • 6.2.10 Sorafenib (Nexavar) - Bayer
• 6.3 Treatment Guidelines Landscape
  • 6.3.1 NCCN Guidelines
  • 6.3.2 ESMO Guidelines
  • 6.3.3 ASCO Guidelines
  • 6.3.4 WHO Obesity and Cancer Prevention Recommendations
• 6.4 Emerging Treatment Trends
  • 6.4.1 Personalized Oncology Approaches
  • 6.4.2 Weight Management Integration in Oncology
  • 6.4.3 Immunometabolism-Based Therapeutics
  • 6.4.4 Preventive Oncology Strategies

7. Epidemiology Forecast Analysis

• 7.1 Forecast Methodology
  • 7.1.1 Historical Epidemiology Assessment
  • 7.1.2 Forecast Modeling Framework
  • 7.1.3 Risk Factor Correlation Analysis
• 7.2 Forecast by Cancer Type
  • 7.2.1 Breast Cancer
  • 7.2.2 Colorectal Cancer
  • 7.2.3 Endometrial Cancer
  • 7.2.4 Liver Cancer
  • 7.2.5 Pancreatic Cancer
  • 7.2.6 Kidney Cancer
  • 7.2.7 Other Obesity-Linked Malignancies
• 7.3 Forecast by Demographics
  • 7.3.1 Adult Population
  • 7.3.2 Geriatric Population
  • 7.3.3 Pediatric and Adolescent Population
  • 7.3.4 Male Population
  • 7.3.5 Female Population

8. Epidemiology Segmentation

• 8.1 By Cancer Type
  • 8.1.1 Breast Cancer
  • 8.1.2 Colorectal Cancer
  • 8.1.3 Endometrial Cancer
  • 8.1.4 Pancreatic Cancer
  • 8.1.5 Liver Cancer
  • 8.1.6 Kidney Cancer
  • 8.1.7 Esophageal Adenocarcinoma
  • 8.1.8 Ovarian Cancer
  • 8.1.9 Thyroid Cancer
  • 8.1.10 Multiple Myeloma
• 8.2 By BMI Classification
  • 8.2.1 Overweight
  • 8.2.2 Obesity Class I
  • 8.2.3 Obesity Class II
  • 8.2.4 Obesity Class III
• 8.3 By Age Group
  • 8.3.1 Pediatric Population
  • 8.3.2 Adult Population
  • 8.3.3 Geriatric Population
• 8.4 By Gender
  • 8.4.1 Male
  • 8.4.2 Female
• 8.5 By Diagnosis Status
  • 8.5.1 Diagnosed Population
  • 8.5.2 Treated Population
  • 8.5.3 Untreated Population

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Regional Obesity Burden
  • 9.1.2 Cancer Incidence Trends
  • 9.1.3 Screening and Diagnostic Access
  • 9.1.4 Treatment Accessibility
  • 9.1.5 Healthcare Infrastructure Assessment
• 9.2 Europe
  • 9.2.1 Regional Epidemiology Trends
  • 9.2.2 Obesity-Driven Cancer Burden
  • 9.2.3 Public Health Initiatives
  • 9.2.4 Treatment Access Landscape
  • 9.2.5 Healthcare System Readiness
• 9.3 Asia-Pacific
  • 9.3.1 Regional Obesity Trends
  • 9.3.2 Rising Cancer Incidence
  • 9.3.3 Healthcare Infrastructure Development
  • 9.3.4 Screening Adoption Trends
  • 9.3.5 Access Challenges
• 9.4 Latin America
  • 9.4.1 Regional Epidemiology Burden
  • 9.4.2 Lifestyle Transition Impact
  • 9.4.3 Treatment Accessibility
  • 9.4.4 Public Health Response
  • 9.4.5 Healthcare Capacity Assessment
• 9.5 Middle East & Africa
  • 9.5.1 Obesity Prevalence Trends
  • 9.5.2 Cancer Burden Assessment
  • 9.5.3 Screening and Diagnosis Challenges
  • 9.5.4 Treatment Access Overview
  • 9.5.5 Public Health Infrastructure

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Epidemiology Overview
  • 10.1.2 Obesity Prevalence Trends
  • 10.1.3 Screening Uptake
  • 10.1.4 FDA Regulatory Framework
  • 10.1.5 Treatment Access and Reimbursement
• 10.2 Canada
  • 10.2.1 Epidemiology Overview
  • 10.2.2 Obesity Burden
  • 10.2.3 Screening Access
  • 10.2.4 Regulatory Framework
  • 10.2.5 Treatment Accessibility
• 10.3 Germany
  • 10.3.1 Epidemiology Overview
  • 10.3.2 Obesity Trends
  • 10.3.3 Healthcare Infrastructure
  • 10.3.4 Regulatory Framework
  • 10.3.5 Reimbursement Landscape
• 10.4 United Kingdom
  • 10.4.1 Epidemiology Overview
  • 10.4.2 Public Health Policies
  • 10.4.3 Screening Programs
  • 10.4.4 Regulatory Framework
  • 10.4.5 Treatment Access
• 10.5 France
  • 10.5.1 Epidemiology Overview
  • 10.5.2 Obesity and Cancer Burden
  • 10.5.3 Healthcare Infrastructure
  • 10.5.4 Regulatory Framework
  • 10.5.5 Reimbursement Analysis
• 10.6 Italy
  • 10.6.1 Epidemiology Overview
  • 10.6.2 Screening Trends
  • 10.6.3 Healthcare Access
  • 10.6.4 Regulatory Framework
  • 10.6.5 Treatment Accessibility
• 10.7 Spain
  • 10.7.1 Epidemiology Overview
  • 10.7.2 Obesity Trends
  • 10.7.3 Public Health Initiatives
  • 10.7.4 Regulatory Framework
  • 10.7.5 Treatment Landscape
• 10.8 China
  • 10.8.1 Epidemiology Overview
  • 10.8.2 Urbanization and Obesity Trends
  • 10.8.3 NMPA Regulatory Framework
  • 10.8.4 Screening Access
  • 10.8.5 Treatment Infrastructure
• 10.9 Japan
  • 10.9.1 Epidemiology Overview
  • 10.9.2 Aging Population Impact
  • 10.9.3 PMDA Regulatory Framework
  • 10.9.4 Screening Programs
  • 10.9.5 Treatment Accessibility
• 10.10 India
  • 10.10.1 Epidemiology Overview
  • 10.10.2 Rising Obesity Burden
  • 10.10.3 CDSCO Regulatory Framework
  • 10.10.4 Diagnostic Accessibility
  • 10.10.5 Treatment Access
• 10.11 South Korea
  • 10.11.1 Epidemiology Overview
  • 10.11.2 Obesity Trends
  • 10.11.3 Healthcare Infrastructure
  • 10.11.4 Regulatory Framework
  • 10.11.5 Reimbursement Landscape
• 10.12 Australia
  • 10.12.1 Epidemiology Overview
  • 10.12.2 Public Health Programs
  • 10.12.3 Screening Trends
  • 10.12.4 Regulatory Framework
  • 10.12.5 Treatment Access
• 10.13 Brazil
  • 10.13.1 Epidemiology Overview
  • 10.13.2 Obesity Burden
  • 10.13.3 Healthcare Capacity
  • 10.13.4 Regulatory Framework
  • 10.13.5 Treatment Accessibility
• 10.14 Mexico
  • 10.14.1 Epidemiology Overview
  • 10.14.2 Lifestyle Transition Impact
  • 10.14.3 Screening Access
  • 10.14.4 Regulatory Framework
  • 10.14.5 Reimbursement Analysis
• 10.15 Saudi Arabia
  • 10.15.1 Epidemiology Overview
  • 10.15.2 Obesity Prevalence Trends
  • 10.15.3 Healthcare Infrastructure
  • 10.15.4 Regulatory Framework
  • 10.15.5 Treatment Access
• 10.16 South Africa
  • 10.16.1 Epidemiology Overview
  • 10.16.2 Public Health Challenges
  • 10.16.3 Diagnostic Accessibility
  • 10.16.4 Regulatory Framework
  • 10.16.5 Treatment Landscape

11. Regulatory & Policy Landscape

• 11.1 United States
  • 11.1.1 FDA Oncology Regulatory Framework
  • 11.1.2 Obesity Prevention Policies
  • 11.1.3 Cancer Screening Recommendations
• 11.2 Europe
  • 11.2.1 EMA Oncology Regulations
  • 11.2.2 EU Public Health Policies
  • 11.2.3 Obesity Reduction Initiatives
• 11.3 Japan
  • 11.3.1 PMDA Oncology Regulations
  • 11.3.2 National Obesity Management Policies
• 11.4 India
  • 11.4.1 CDSCO Oncology Framework
  • 11.4.2 National Cancer Control Programs
• 11.5 China
  • 11.5.1 NMPA Regulatory Environment
  • 11.5.2 Public Health and Obesity Policies
• 11.6 Global Public Health Initiatives
  • 11.6.1 WHO Obesity Prevention Framework
  • 11.6.2 International Cancer Prevention Programs
  • 11.6.3 Population Screening Strategies

12. Competitive Landscape

• 12.1 Epidemiology Research Ecosystem
  • 12.1.1 Academic Research Institutions
  • 12.1.2 Oncology Research Networks
  • 12.1.3 Public Health Organizations
• 12.2 Strategic Collaborations
  • 12.2.1 Oncology Research Partnerships
  • 12.2.2 Diagnostic Collaborations
  • 12.2.3 Public-Private Partnerships
• 12.3 Clinical Development Trends
  • 12.3.1 Immunotherapy Expansion
  • 12.3.2 Metabolic Oncology Research
  • 12.3.3 Biomarker-Based Clinical Programs

13. Company Profiles

• 13.1 F. Hoffmann-La Roche
  • 13.1.1 Oncology Portfolio Overview
  • 13.1.2 Biomarker Integration Strategy
  • 13.1.3 Immuno-Oncology Programs
  • 13.1.4 Clinical Development Activities
• 13.2 Merck & Co.
  • 13.2.1 Oncology Portfolio Overview
  • 13.2.2 Keytruda Expansion Strategy
  • 13.2.3 Precision Oncology Programs
  • 13.2.4 Clinical Trial Activities
• 13.3 Bristol Myers Squibb
  • 13.3.1 Immuno-Oncology Leadership
  • 13.3.2 Cell Therapy Programs
  • 13.3.3 Clinical Development Activities
  • 13.3.4 Strategic Collaborations
• 13.4 AstraZeneca
  • 13.4.1 Targeted Oncology Portfolio
  • 13.4.2 Lung Cancer Programs
  • 13.4.3 ADC Development Strategy
  • 13.4.4 Clinical Expansion Activities
• 13.5 Pfizer
  • 13.5.1 Precision Oncology Portfolio
  • 13.5.2 Targeted Therapy Programs
  • 13.5.3 Global Clinical Expansion
  • 13.5.4 Biomarker Strategy
• 13.6 Novartis
  • 13.6.1 Radioligand Therapy Programs
  • 13.6.2 Cell and Gene Therapy Activities
  • 13.6.3 Oncology Clinical Development
  • 13.6.4 Strategic Research Focus
• 13.7 Johnson & Johnson
  • 13.7.1 Oncology Clinical Programs
  • 13.7.2 Combination Therapy Strategy
  • 13.7.3 Hematologic Oncology Focus
  • 13.7.4 Commercialization Approach
• 13.8 Gilead Sciences
  • 13.8.1 Cell Therapy Programs
  • 13.8.2 ADC Clinical Development
  • 13.8.3 Manufacturing Expansion
  • 13.8.4 Oncology Research Strategy

14. Future Outlook

• 14.1 Future Epidemiology Trends
  • 14.1.1 Global Obesity Burden Forecast
  • 14.1.2 Future Cancer Incidence Projection
  • 14.1.3 Early-Onset Cancer Trends
• 14.2 Emerging Public Health Priorities
  • 14.2.1 Preventive Oncology Expansion
  • 14.2.2 Lifestyle Intervention Programs
  • 14.2.3 AI-Based Risk Prediction Integration
• 14.3 Future Treatment Paradigm
  • 14.3.1 Precision Prevention Strategies
  • 14.3.2 Immunometabolism Research Expansion
  • 14.3.3 Personalized Oncology Approaches
• 14.4 Strategic Recommendations
  • 14.4.1 Screening Expansion Priorities
  • 14.4.2 Healthcare Infrastructure Development
  • 14.4.3 Research Investment Priorities

15. Methodology

• 15.1 Research Methodology
  • 15.1.1 Primary Research
  • 15.1.2 Secondary Research
  • 15.1.3 Expert Interviews
• 15.2 Data Sources and Validation
  • 15.2.1 Epidemiology Databases
  • 15.2.2 Regulatory Databases
  • 15.2.3 Academic Publications
  • 15.2.4 Public Health Sources
• 15.3 Forecasting Methodology
  • 15.3.1 Historical Trend Analysis
  • 15.3.2 Risk Correlation Modeling
  • 15.3.3 Population Projection Models
• 15.4 Assumptions and Limitations
  • 15.4.1 Data Assumptions
  • 15.4.2 Research Constraints